Trial Profile

Comparative and Pragmatic Study of Simponi Aria Versus Remicade in Rheumatoid Arthritis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 24 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Golimumab (Primary) ; Infliximab (Primary)
Indications Rheumatoid arthritis
Focus Adverse reactions
Acronyms AWARE
Sponsors Janssen

Most Recent Events

05 Jun 2021 Results of a post hoc analysis assessing the safety and efficacy of IV GLM and IFX in elderly presented at the 22nd Annual Congress of the European League Against Rheumatism
05 Jun 2021 Results assessing the patient reported outcomes of Golimumab and infliximab in patients with rheumatoid arthritis, presented at the 22nd Annual Congress of the European League Against Rheumatism.
06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com